vs
Kimco Realty（KIM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Kimco Realty的1.4倍（$772.1M vs $542.5M），Kimco Realty净利率更高（27.9% vs 12.7%，领先15.1%），Revvity同比增速更快（5.9% vs 3.2%），过去两年Revvity的营收复合增速更高（9.0% vs 3.8%）
Kimco Realty是总部位于美国纽约州杰里科的房地产投资信托企业，核心投资领域为购物中心类商业地产，在商业不动产投资及运营领域积累了深厚的行业经验与资源优势。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
KIM vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$542.5M
营收增速更快
RVTY
高出2.6%
3.2%
净利率更高
KIM
高出15.1%
12.7%
两年增速更快
RVTY
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $542.5M | $772.1M |
| 净利润 | $151.2M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 36.4% | 14.5% |
| 净利率 | 27.9% | 12.7% |
| 营收同比 | 3.2% | 5.9% |
| 净利润同比 | -9.0% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KIMRVTY
| Q4 25 | $542.5M | $772.1M | ||
| Q3 25 | $535.9M | $698.9M | ||
| Q2 25 | $525.2M | $720.3M | ||
| Q1 25 | $536.6M | $664.8M | ||
| Q4 24 | $525.4M | $729.4M | ||
| Q3 24 | $507.6M | $684.0M | ||
| Q2 24 | $500.2M | $691.7M | ||
| Q1 24 | $503.8M | $649.9M |
净利润KIMRVTY
| Q4 25 | $151.2M | $98.4M | ||
| Q3 25 | $137.8M | $46.7M | ||
| Q2 25 | $163.0M | $53.9M | ||
| Q1 25 | $132.8M | $42.2M | ||
| Q4 24 | $166.0M | $94.6M | ||
| Q3 24 | $136.0M | $94.4M | ||
| Q2 24 | $119.7M | $55.4M | ||
| Q1 24 | $-11.0M | $26.0M |
毛利率KIMRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率KIMRVTY
| Q4 25 | 36.4% | 14.5% | ||
| Q3 25 | 34.9% | 11.7% | ||
| Q2 25 | 39.2% | 12.6% | ||
| Q1 25 | 33.6% | 10.9% | ||
| Q4 24 | 31.7% | 16.3% | ||
| Q3 24 | 33.7% | 14.3% | ||
| Q2 24 | 32.1% | 12.4% | ||
| Q1 24 | 25.9% | 6.8% |
净利率KIMRVTY
| Q4 25 | 27.9% | 12.7% | ||
| Q3 25 | 25.7% | 6.7% | ||
| Q2 25 | 31.0% | 7.5% | ||
| Q1 25 | 24.8% | 6.4% | ||
| Q4 24 | 31.6% | 13.0% | ||
| Q3 24 | 26.8% | 13.8% | ||
| Q2 24 | 23.9% | 8.0% | ||
| Q1 24 | -2.2% | 4.0% |
每股收益（稀释后）KIMRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $211.6M | $919.9M |
| 总债务越低越好 | $7.7B | — |
| 股东权益账面价值 | $10.4B | $7.3B |
| 总资产 | $19.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资KIMRVTY
| Q4 25 | $211.6M | $919.9M | ||
| Q3 25 | $159.3M | $931.4M | ||
| Q2 25 | $226.6M | $991.8M | ||
| Q1 25 | $131.3M | $1.1B | ||
| Q4 24 | $688.6M | $1.2B | ||
| Q3 24 | $789.0M | $1.2B | ||
| Q2 24 | $126.4M | $2.0B | ||
| Q1 24 | $133.4M | $1.7B |
总债务KIMRVTY
| Q4 25 | $7.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.0B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益KIMRVTY
| Q4 25 | $10.4B | $7.3B | ||
| Q3 25 | $10.5B | $7.4B | ||
| Q2 25 | $10.5B | $7.6B | ||
| Q1 25 | $10.6B | $7.6B | ||
| Q4 24 | $10.7B | $7.7B | ||
| Q3 24 | $10.5B | $7.9B | ||
| Q2 24 | $10.6B | $7.9B | ||
| Q1 24 | $10.6B | $7.8B |
总资产KIMRVTY
| Q4 25 | $19.7B | $12.2B | ||
| Q3 25 | $19.9B | $12.1B | ||
| Q2 25 | $19.8B | $12.4B | ||
| Q1 25 | $19.7B | $12.4B | ||
| Q4 24 | $20.3B | $12.4B | ||
| Q3 24 | $20.1B | $12.8B | ||
| Q2 24 | $19.5B | $13.4B | ||
| Q1 24 | $19.5B | $13.4B |
负债/权益比KIMRVTY
| Q4 25 | 0.74× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $258.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | 0.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.71× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流KIMRVTY
| Q4 25 | $258.4M | $182.0M | ||
| Q3 25 | $332.4M | $138.5M | ||
| Q2 25 | $305.4M | $134.3M | ||
| Q1 25 | $223.8M | $128.2M | ||
| Q4 24 | $239.5M | $174.2M | ||
| Q3 24 | $295.9M | $147.9M | ||
| Q2 24 | $294.1M | $158.6M | ||
| Q1 24 | $176.1M | $147.6M |
自由现金流KIMRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | $205.4M | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率KIMRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | 38.3% | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度KIMRVTY
| Q4 25 | 0.0% | 2.6% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 3.4% | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率KIMRVTY
| Q4 25 | 1.71× | 1.85× | ||
| Q3 25 | 2.41× | 2.97× | ||
| Q2 25 | 1.87× | 2.49× | ||
| Q1 25 | 1.69× | 3.03× | ||
| Q4 24 | 1.44× | 1.84× | ||
| Q3 24 | 2.18× | 1.57× | ||
| Q2 24 | 2.46× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KIM
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
